Povezanost protutijela na receptor za M-tip fosfolipazu A2 s kliničkim karakteristikama i ishodom bolesnika s primarnom membranskom nefropatijom u 5-godišnjem praćenju by Mario Laganović et al.
Acta Clin Croat (Suppl. 1) 2021; 60:71-77 Original Scientific Paper
doi: 10.20471/acc.2021.60.s1.11
Acta Clin Croat, Vol. 60, (Suppl. 1) 2021  71
ASSOCiAtiOn Of the AutOAntibOdieS tO M-tyPe 
PhOSPhOliPASe A2 reCePtOr titer with CliniCAl 
ChArACteriStiCS And OutCOMe Of PAtientS  
with PriMAry MeMbrAnOuS nePhrOPAthy  
– 5-yeAr fOllOw uP Study
Mario laganović1, ivica horvatić2, ivan bubić3, Mario ilić4, bojana Maksimović5,  
Ana Kozmar6, ivana Vuković brinar1, Matija Crnogorac2, Marijana Živko7,  
Margareta fištrek6, Željka Jureković5, danica Galešić ljubanović2, Marijana Ćorić1,  
Stela bulimbašić1, Krešimir Galešić1 and Mladen Knotek5
1university hospital Center Zagreb, Zagreb; School of Medicine, university of Zagreb, Zagreb;  
2dubrava university hospital, Zagreb; School of Medicine, university of Zagreb, Zagreb;  
3university hospital Center rijeka, rijeka; School of Medicine, university of rijeka, rijeka;  
4dubrovnik County hospital, dubrovnik;  
5Merkur university hospital, Zagreb; School of Medicine, university of Zagreb Zagreb;  
6university hospital Center Zagreb, Zagreb;  
7university hospital Center Zagreb, Zagreb; School of Medicine, J.J. Strossmayer university of Osijek
SuMMAry – Introduction: primary membranous nephropathy (pMn) is glomerulopathy caused 
in the majority of cases by autoantibodies to Phospholipase-A2 receptors (PlA2r-Ab). This study 
aimed to evaluate the clinical course and outcomes of the patients with pMn regarding PlA2r-Ab 
status.
Patients and methods: 32 patients (21 males, 11 females) with renal biopsy-proven pMn were 
 included in the study. PlA2r-Ab (eliSA method) and outcomes (defined according to KdiGO) 
were evaluated after 21 and 64 months of follow-up in 28 patients.
Results: 19 patients had positive PlA2r-Ab (>20 ru/ml) (59.3%), with median titer of 97  
(21-1418 ru/ml). The rate of remission in low PlA2r-Ab titer group (< 200 ru/ml) after 21 
months was significantly higher than in high PlA2r-Ab group (> 200 ru/ml) (90% vs. 50%, 
p=0.045), and after 64 months the difference was not significant (80% vs. 50%, p=0.210). The relapse 
rate after 64 months was higher in the high PlA2r-Ab group (87% vs. 63%). Multivariant linear 
regression found serum creatinine (ß=0.682, p<0.001) and PlA2r-Ab (ß=0.527, p<0.001) as signifi-
cant predictors for kidney function at the end of follow-up.
Conclusion: higher titers of PlA2r-Ab are related to worse kidney function outcome, higher  
24-hour proteinuria, and a higher number of relapses in patients with pMn.
Key words: membranous nephropathy, M-type phospholipase A2 receptor, autoantibodies, glomerulone-
phritis
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Primary membranous nephropathy (Mn) is an 
 autoimmune glomerular disease characterized by the 
presence of autoantibodies to podocyte membrane 
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 antigens and the formation of subepithelial immune 
complexes. Clinically it manifests as nephrotic syn-
drome and it is the most common cause of nephrotic 
syndrome in Caucasian adults1-5. Approximately one 
third of the patients enter spontaneous remission, and 
one third develop advanced chronic kidney disease, 
some of them requiring renal replacement therapy af-
ter 15 years1,2,6. in the last 10 years, significant progress 
was made in clarifying the etiopathogenesis of the dis-
ease. As major podocyte autoantigen, M-type phos-
pholipase A2 receptor (PlA2r) was found, account-
ing for 50-80% of the cases of primary Mn7-9. Other 
podocyte membrane autoantigens found so far in pri-
mary Mn are thrombospondin type-1 domain-con-
taining 7A (thSd7A)10, neural epidermal growth 
factor-like 1 protein (nell-1)11, neutral endopepti-
dase (neP)12, and exostosin1/exostosin213. There are 2 
routinely used methods for determining PlA2r auto-
antibodies (PlA2r-Ab): indirect immunofluores-
cence (iif), which is semiquantitative and more sensi-
tive, and the eliSA method, which is quantitative and 
somewhat less sensitive8,14,15. There is still no consensus 
regarding the optimal cut-off values for positive find-
ings, with the majority of studies using the cut-off 
value of 14-20 ru/ml in the eliSA test. There was a 
recent proposal for lowering the cut-off value to 2 ru/
ml16. numerous studies show the correlation between 
the titer of PlA2r-Ab and the clinical course of the 
disease, but the true prognostic significance of the 
PlA2r-Ab titer regarding kidney outcomes is still 
yet to be determined4,8,16-18. in this retrospective study, 
we have explored the correlation of PlA2r-Ab status 
with clinical course and outcomes in patients with pri-
mary Mn.
Patients and methods
The examined group consisted of 32 patients (21 
males, 11 females), with a median age of 55.5 years 
(range 20 – 81 years) with renal biopsy and clinically 
proven pMn. Patients with a secondary form of Mn 
were excluded from the study on a histological and 
clinical basis (negative serologic tests for lupus erythe-
matosus and hepatitis, exclusion of malignancies de-
pending on the age, etc.). during follow-up, all pa-
tients were treated according to KdiGO guidelines by 
the decision of the treating physician19. Outcomes 
were evaluated after 21 and 64 months of follow-up in 
28 patients. The following variables were measured at 
the time of renal biopsy and during the follow-up vis-
its: body proportions, blood pressure (bP), serum cre-
atinine (SCr), estimated glomerular filtration rate 
(eGfr), 24h proteinuria (uP), serum albumin (SAlb) 
and PlA2r-Ab (eliSA method, euroimmun AG, 
lübeck, Germany). hypertension was considered 
blood pressure > 140/90 mmhg, increased serum cre-
atinine as > 104 µmol/l, and stages of chronic kidney 
disease were defined after KdiGO guidelines20, ne-
phrotic proteinuria was defined as > 3.5 g/du. Accord-
ing to the manufacturer, the eliSA results were con-
sidered positive at a level >20 ru/ml for igG PlA2r-
Ab. further categorization into groups was made ac-
cording to PlA2r-Ab levels: lower levels group (< 
200 ru/ml) and higher levels group (> 200 ru/ml). 
Outcomes were defined as complete remission (24-
hour proteinuria < 0.3g, normal SCr and eGfr), par-
tial remission (24-hour proteinuria < 3.5g, or reduc-
tion for >50% from basal values, stable SCr or eGfr), 
no remission (unchanged or worsened initial parame-
ters of renal function and proteinuria) and relapse (24-
hour proteinuria > 3.5g and signs of nephrotic syn-
drome after achieving complete or partial remission).
Statistical analysis
data are given as mean values+/-Sds or median 
values and ranges when appropriate. Patients were di-
vided into two groups corresponding to the levels 
PlA2r-Ab level at the start of the study (low and 
high). differences in means between groups were as-
sessed by Student’s t-test. A c2 test or fisher exact test 
was used for group comparisons regarding prevalence. 
relationships between antiPlA2r-Ab levels and 
clinical and laboratory parameters were examined by 
Pearson’s correlation coefficient (r). Multivariant linear 
regression analysis was performed to quantify the 
strength of the association between antiPlA2r levels 
and several relevant variables. All results were consid-
ered statistically significant if p < 0.05. Statistical anal-
ysis was performed using StAtiStiCA, vers.8 (Stat-
Soft., inc).
Results
Clinical and laboratory characteristics of all sub-
jects and regarding positivity of PlA2r-Ab are 
shown in table 1.
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Table 1. Clinical and laboratory characteristics of all subjects and regarding positivity of PLA2R-AB
whole goup
n=32
PlA2r-Ab < 20 ru/ml
n = 13
PlA2r-Ab ≥ 20 ru/ml
n = 19 p
Age (years) 53.7 ± 13.5 57.0 ± 15.2 51.5 ± 12.2 0.269
Males (n/%) 21 / 65 9 / 69.2 12 / 63. 1 0.521 
Serum creatinine (µmol/l) 114.7 ± 58.1 116.1 ± 76.5 99.2 ± 34.9 0.081
eGfr (ml/min/1.73m2) 72.3 ± 31.3 65.2 ± 36.5 77.5 ± 26.8 0.286
24h proteinuria (g/du) 7.92 ± 4.36 7.08 ± 4.68 8.53 ± 4.15 0.371
Serum albumin (g/l) 28.8 ± 6.4 31.1 ± 5.5 27.2 ± 6.7 0.126
PlA2r-Ab (ru/ml) 138.1 ± 268 2.1 ± 1.3 231.3 ± 318.3 0.015
Systolic bP (mmhg) 145.5 ± 18.9 148.7 ± 22.8 143.4 ± 15.9 0.452
diastolic bP (mmhg) 87.6 ± 20.1 85.1 ± 28.6 89.4 ± 11.7 0.556
time to remission (months) 7.9 ± 4.4 8.8 ± 5.4 7.4 ± 3.9 0.497
Table 2. Clinical and laboratory characteristics of subjects regarding levels of PLA2R-AB
PlA2r-Ab < 200 ru/ml
n = 11
PlA2r-Ab ≥ 200 ru/ml
n = 8 p
Age (years) 53 ± 11.1 49.5 ± 14.2 0.554
Males (n/%) 6 ± 54.5 6 ± 75.0 0.361
Serum creatinine (µmol/l) 96.7 ± 33.5 103.1 ± 39.3 0.715
eGfr (ml/min/1.73m2) 77.2 ± 25.8 78.1 ± 30.5 0.945
24h proteinuria (g/du) 8.41 ± 4.32 8.72 ± 4.21 0.881
Serum albumin (g/l) 28.4 ± 7.1 24.7 ± 5.4 0.311
PlA2r-Ab (ru/ml) 61.9 ± 31.8 464.2 ± 389.9 0.003
Systolic bP (mmhg) 140.4 ± 12.7 147.6 ± 19.7 0.348
diastolic bP (mmhg) 84.8 ± 11.2 95.7 ± 9.9 0.041
time to remission (months) 7.4 ± 3.9 7.5 ± 4.6 0.967
Figure 1. Outcome of renal function and proteinuria at the end of follow-up according to PLA2R-AB titer
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nineteen patients (59.3%) had positive PlA2r-
Ab (>20 ru/ml). There was no difference in basal val-
ues of bP, SCr, eGfr, 24-hour proteinuria, and SAlb 
according to negative or positive PlA2r-Ab status. 
There were also no differences according to gender.
Clinical and laboratory characteristics of subjects 
regarding levels of PlA2r-Ab are shown in table 2.
Patients with lower PlA2r-Ab titer (<200 ru/
ml) had significantly higher rates of remission after 21 
months, compared to patients with higher PlA2r-
Ab titer (> 200 ru/ml) (90% vs. 50%, χ2 4.0, p=0.045), 
and after 64 months the remission rate was still higher 
in low titer group, but the difference was not statisti-
cally significant anymore (80% vs. 50%, χ2 1.57, 
p=0.210). The outcome of renal function and protein-
uria at the end of follow-up according to PlA2r-Ab 
titer is shown in figure 1.
The highest values of PlA2r-Ab titer were found 
in patients without remission (88 vs. 265 ru/ml; 
p=0.093). 87% of patients with high PlA2r-Ab titer 
had at least one relapse in 64 months vs. 63% in pa-
tients with low PlA2r-Ab titer (χ2 1.68, p=0.194). 
After 21 months, there were 71% of patients in remis-
sion and 63% after 64 months. There was a positive 
correlation between PlA2r-Ab titer and SCr and 
PlA2r-Ab titer and 24-hour proteinuria after 21 
months (figure 2). Multivariant linear regression anal-
ysis found SCr and PlA2r-Ab as significant pre-
dictors for kidney function at the end of follow-up 
(table 3). PlA2r-Ab titer was an independent sig-
nificant prognostic factor for 24-hour proteinuria at 
the end of follow-up (table 4).
Discussion
This study examined the temporal relationship be-
tween PlA2r-Ab titer and clinical course in a cohort 
of Croatian primary Mn patients. The incidence of 
PlA2r-Ab in this study was 59.3%, comparable to 
the reported incidence of PlA2r-associated primary 
Mn of 50-80%8,9,14. This variable incidence results 
from different cut-off values used, different timing re-
Figure 2. Correlation between PLA2R-AB titer and serum creatinine and 24-hour proteinuria  
after 21 months follow-up.
Table 3. Multivariant linear regression analysis  
of several variables on serum creatinine  
at the end of follow-up
ß Se p
Systolic bP -0.219 0.131 0.105
PlA2r- Ab 0.527 0.124 <0.001
Serum creatinine  
(at the time of renal biopsy) 0.682 0.133 <0.001
24h proteinuria  
(at the time of renal biopsy) 0.110 0.126 0.391
Table 4. Multivariant linear regression analysis  
of several variables on 24h proteinuria  
at the end of follow-up
ß Se p
Systolic bP -0.207 0.169 0.232
PlA2r- Ab 0.544 0.161 0.002
Serum creatinine  
(at the time of renal biopsy) 0.097 0.173 0.580
24h proteinuria  
(at the time of renal biopsy) 0.104 0.163 0.5299
M. Laganović et al. Association of antiPLA2R titer with outcome in membranous nephropathy
Acta Clin Croat, Vol. 60, (Suppl. 1) 2021 75
garding sampling in relation to the beginning of the 
disease, and different ethnicity. lower incidences of 
around 50% are reported in Japanese patients21. we 
used the cut-off value of 20 ru/ml, which was used in 
the majority of studies and also recommended by the 
manufacturer, euroimmun assay15,18. The diagnostic 
significance of PlA2r-Ab has been confirmed and 
validated by numerous studies and generally is not dis-
puted. Specificity and sensitivity of PlA2r-Ab in 
differentiating between primary and secondary Mn 
varies between studies, and a recent meta-analysis of 
35 studies on 6085 patients by li w et al., found the 
specificity of 97% and sensitivity of 65%22. There was 
no difference found in basal clinical characteristics be-
tween PlA2r-Ab positive and negative patients, 
which is concordant with other studies, except that 
some studies found a correlation between 24-hour 
proteinuria at the beginning of the disease and 
PlA2r-Ab titer, which we did not found23. The tem-
poral association between PlA2r-Ab status and 
clinical course of primary Mn (mostly represented by 
24-hour proteinuria) has also been well estab-
lished4,8,16-18. immunological activation of the disease 
precedes clinical signs for around 3 months24. equally, 
clinical remission usually follows immunological re-
mission by several months, as in spontaneous remis-
sion, as well as in therapy-induced remission8,17,18,25. 
hence, most clinicians agree on the necessity of serial 
PlA2r-Ab titer monitoring in primary Mn pa-
tients26. The optimal interval for this is still yet to be 
determined, but it should be at least every 6 months. in 
most of the studies, there is a correlation between the 
PlA2r-Ab titer and clinical outcomes of the disease. 
Spontaneous remission was more likely to occur in pa-
tients with a lower PlA2r-Ab titer or with negative 
PlA2r-Ab27,28. reduction or disappearance of 
PlA2r-Ab titer is associated with therapy-induced 
partial or complete remission in primary Mn18,29-38. in 
our study, a significant difference was found in achiev-
ing remission at 21 months, regarding PlA2r-Ab 
titer, but not after 64 months. Possible explanations for 
this finding include a smaller number of patients to 
achieve statistical significance and also a relapsing-re-
mitting course of the disease, especially in long-dura-
tion follow-up. There are still some discrepancies re-
garding the prognostic significance of PlA2r-Ab, 
which was also the main focus of our study. Primary 
Mn typically is a slow progressive disease, and hard 
kidney endpoints (end-stage kidney disease eSKd; 
50%-reduction in eGfr) are achieved after a long pe-
riod of time. PlA2r-Ab is known for about 10 years, 
and this interval is probably not long enough to have 
significant data on its prognostic value on hard kidney 
endpoints. nonetheless, some studies have found that 
PlA2r-Ab has prognostic significance. Mahmud M 
et al. found that a higher PlA2r-Ab titer was associ-
ated with a higher risk of worsening kidney function 
(doubling serum creatinine)39. Similar was found by 
Qu Z et al.30, Song eJ et al.40 and Kanigicherla d. et 
al.41. On the contrary, Guo n et al.31 didn’t find 
PlA2r-Ab titer as a significant predictor for kidney 
function during follow-up. A meta-analysis of 11 
studies and 824 patients by liang y et al. found that 
PlA2r-Ab titer was a significant predictor for the 
remission of the disease and renal failure, but not for 
the relapse of the disease38. in our study, we found 
PlA2r-Ab, as well as serum creatinine as indepen-
dent significant predictors for kidney function at the 
end of follow-up, and patients with higher PlA2r-
Ab titer had a greater risk for relapse. Also, we used a 
multivariable method to establish prognostic factors 
for kidney function, which is one of the strengths of 
our study.
Our study is limited by a relatively small number of 
patients, which lowers its statistical power. The retro-
spective nature of the study, different treatment sched-
ules and not considering pathohistological findings 
represent other limitations to our study.
nonetheless, this study is first in Croatian patients 
with primary membranous nephropathy to evaluate 
the status and prognostic significance of PlA2r-Ab 
titer. Along with other published studies, it should 
contribute to better understanding the role of PlA2r-
Ab as a serologic marker in diagnosing the disease and 
also supporting its use in a personalized approach to 
prognosis and primary Mn treatment.
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Sažetak
POVeZAnOSt PrOtutiJelA nA reCePtOr  
ZA M-tiP fOSfOliPAZu A2 S KliniČKiM KArAKteriStiKAMA  
i iShOdOM bOleSniKA S PriMArnOM MeMbrAnSKOM nefrOPAtiJOM  
u 5-GOdiŠnJeM PrAĆenJu
M. Laganović, I. Horvatić, I. Bubić, M. Ilić, B. Maksimović, A. Kozmar, I. Vuković Brinar, M. Crnogorac, M. Živko,  
M. Fištrek, Ž. Jureković, D. Galešić Ljubanović, M. Ćorić, S. Bulimbašić, K. Galešić i M. Knotek
Uvod: primarna membranska nefropatija (pMn) je glomerulopatija, koja je u većini slučajeva uzrokovana autoprotutije-
lima na receptor za fosfolipazu A2 (PlA2r-Pt). Cilj ovog istraživanja bio je analizirati povezanost PlA2r-Pt s kliničkim 
tijekom i ishodima bolesti.
Ispitanici i metode: 32 bolesnika (21 muškaraca, 11 žena), s biopsijom bubrega dijagnosticiranim pMn, bilo je uključeno 
u istraživanje. PlA2r-Pt (eliSA metoda) i ishodi (definirani u skladu s KdiGO) određeni su nakon 21 i 64 mjeseca 
praćenja u 28 bolesnika.
Rezultati: 19 bolesnika imalo je pozitivna PlA2r-Pt (>20 ru/ml) (59.3%), s medijanom titra 97 (21-1418 ru/ml). 
Stopa remisije u skupini s niskim titrom PlA2r-Pt (< 200 ru/ml) nakon 21 mjeseca bila je značajno viša u odnosu na 
skupinu s visokim titrom PlA2r-Pt (> 200 ru/ml) (90% vs. 50%, p=0.045), a nakon 64 mjeseca razlika nije bila značajna 
(80% vs 50%, p=0.210). Stopa relapsa nakon 64 mjeseca bila je viša u skupini s visokim titrom PlA2r-Pt (87% vs. 63%). 
Multivarijatnom linearnom regresijom su kao značajni neovisni prediktori za bubrežnu funkciju na kraju praćenja nađeni 
serumski kreatinin (ß=0.682, p<0.001) i PlA2r-Pt (ß=0.527, p<0.001).
Zaključak: viši titar PlA2r-Pt povezan je s lošijim ishodom bubrežne funkcije, višom 24-satnom proteinurijom i većom 
stopom relapsa u bolesnika s pMn.
Ključne riječi: membranska nefropatija, protutijela na M-tip receptora za fosfolipazu A2, glomerulonefritis
